A Study of DTC in Patients With AIDS and AIDS Related Complex

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merieux Institute
• Treatments: Ditiocarb

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Active opportunistic infection or progressive Kaposi's sarcoma (KS).

• Dementia.

• Lymphoma.

Concurrent Medication:

Excluded within 3 weeks of study entry:

• Other experimental AIDS therapy.

Patients with the following are excluded:

• Active opportunistic infection or progressive Kaposi's sarcoma (KS).

Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.